IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 13.1 SEK 8.26% Market Closed
Market Cap: 678.4m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

IRLAB Therapeutics AB
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IRLAB Therapeutics AB
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
IRLAB Therapeutics AB
STO:IRLAB A
Accrued Liabilities
kr14.9m
CAGR 3-Years
8%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Accrued Liabilities
kr252.1m
CAGR 3-Years
67%
CAGR 5-Years
106%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Accrued Liabilities
kr251.8m
CAGR 3-Years
22%
CAGR 5-Years
22%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Accrued Liabilities
kr78.5m
CAGR 3-Years
53%
CAGR 5-Years
94%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Accrued Liabilities
kr9.2m
CAGR 3-Years
-30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Accrued Liabilities
kr5.4m
CAGR 3-Years
24%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
No Stocks Found

IRLAB Therapeutics AB
Glance View

Market Cap
679.5m SEK
Industry
Pharmaceuticals

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

IRLAB A Intrinsic Value
16.06 SEK
Undervaluation 18%
Intrinsic Value
Price

See Also

What is IRLAB Therapeutics AB's Accrued Liabilities?
Accrued Liabilities
14.9m SEK

Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's Accrued Liabilities amounts to 14.9m SEK.

What is IRLAB Therapeutics AB's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
38%

Over the last year, the Accrued Liabilities growth was 11%. The average annual Accrued Liabilities growth rates for IRLAB Therapeutics AB have been 8% over the past three years , 38% over the past five years .

Back to Top